Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform

Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, announced a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids.

Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in the creation of novel capsids with the potential to power programs in Voyager’s pipeline and supporting Voyager alliances with leading biopharma partners.

Touchlight’s enzymatically amplified doggybone DNA technology enables the rapid and scalable amplification of DNA regardless of sequence length or complexity and is being deployed across genetic medicine applications including mRNA, AAV, lentivirus, genome editing and DNA vaccines. doggybone DNA is amplified in vitro, avoiding the constraints of using cells for DNA amplification, thus also enabling applications such as the production of high-diversity DNA libraries.

Karen Fallen, Group CEO of Touchlight, commented: “Today’s announcement is another example of the power and breadth of application of the doggybone DNA platform. We’re delighted that the platform is being utilised to contribute to the advancement of novel gene therapies for diseases of high unmet medical need.”

Financial terms are not disclosed.